So erreichen Sie uns:

Gebührenfreie Rufnummer

Österreich, Tschechien, Frankreich, Deutschland, Italien, Polen, Spanien, Schweiz, Türkei und Großbritannien
+ 800 624 367 23
+ 800 MAGFORCE
Vereinigte Staaten, Kanada, Guam, Puerto Rico und US-Jungferninseln
+ 1 844 833 9623
Rufnummern weitere Länder
Nachricht schreiben
How to reach us:

Toll-free phone number

Austria, Czech Republic, France, Germany, Italy, Poland, Spain, Switzerland, Turkey and Great Britain
+ 800 624 367 23
+ 800 MAGFORCE
United States, Canada, Guam, Puerto Rico and US Virgin Islands
+ 1 844 833 9623
Phone numbers for other countries
Write a message

Patient case report on the use of the NanoTherm® therapy for the treatment of relapsed glioblastoma after resection

Course of disease in a 39-year-old-patient

Diagnosis

On January 5, 2007 a histologically confirmed glioblastoma, WHO Grade IV, temporo-occipital right, was diagnosed in the 39-year-old patient. On January 8, 2007, the tumor was completely resected. Treatment with Temozolomide was started on January 17, 2007, with a concomitant radiotherapy with a total of 59.4 Gy (1.8 Gy/d) from January 30 – March 15, 2007. From April 25 – May 16, 2007, the patient was treated exclusively with Temozolomide.

Decision for NanoTherm® Therapy

On May 18, 2007 a relapse with a tumor volume of 2.5 ml was diagnosed by CT scan on the temporo-occipital right within the former tumor resection area. The treating neurosurgeons did not recommend resection of the relapse because of a possible hemiparesis, and instead decided to treat with NanoTherm® therapy.

Therapy

  • Intervention with 5 punctures on July 11, 2007
  • Treatment of patient with alternating magnetic field in the NanoActivator® (July 18 - August 3, 2007: twice a week for 1 hour over a period of 3 weeks, in total 6 sessions)
  • Simultaneous radiotherapy with a total does of 29.9 Gy (13 x 2.3 Gy)

Side effects

The only reported side effect from the NanoTherm® therapy was sweating. No other side effects or complaints were reported by the patient.

Results

  • CT follow-up scans performed at 2, 4, 7, 10, 14, 18, 22 and 24 months after completion of NanoTherm® Therapy showed no indication of a tumor relapse
  • Last contact: June 2011, the patient is alive (47 months)

NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide certification (CE mark) as medical devices for the treatment of brain tumors. NanoTherm® therapy is currently available to national and foreign patients in dedicated hospitals in Germany.

Contact

For more information, please contact our Patient Services under T: +49 30 - 30 83 80 - 73 (free call within Germany: 0800 - 66 46 46 1) or ask your physician. You can also write us at